{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:28:54Z","timestamp":1790256534119,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,15]]},"DOI":"10.1086\/518148","type":"journal-article","created":{"date-parts":[[2007,6,18]],"date-time":"2007-06-18T16:37:38Z","timestamp":1182184658000},"page":"S56-S60","source":"Crossref","is-referenced-by-count":56,"title":["Dengue Vaccines Approach the Finish Line"],"prefix":"10.1093","volume":"45","author":[{"given":"Robert","family":"Edelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,7,15]]},"reference":[{"key":"key\n\t\t\t\t20171014000805_ref1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0966-842X(01)02288-0","article-title":"Epidemic dengue\/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century","volume":"10","author":"Gubler","year":"2002","journal-title":"Trends Microbiol"},{"key":"key\n\t\t\t\t20171014000805_ref2","volume-title":"World distribution of dengue\u20142003","author":"Centers for Disease Control and Prevention"},{"key":"key\n\t\t\t\t20171014000805_ref3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1128\/CMR.3.4.376","article-title":"The dengue viruses","volume":"3","author":"Henchal","year":"1990","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20171014000805_ref4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0264-410X(03)00533-4","article-title":"Policymakers' views on dengue fever\/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries","volume":"22","author":"DeRoeck","year":"2003","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014000805_ref5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1056\/NEJMoa051331","article-title":"Spectrum of disease and relation to place of exposure among ill returned travelers","volume":"354","author":"Freedman","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014000805_ref6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4269\/ajtmh.1952.1.30","article-title":"Research on dengue in World War II","volume":"1","author":"Sabin","year":"1952","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20171014000805_ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690001","article-title":"Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command","volume":"69","author":"Innis","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20171014000805_ref8","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.vaccine.2004.11.040","article-title":"Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014000805_ref9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0065-3527(03)59009-1","article-title":"Microevolution and virulence of dengue viruses","volume":"59","author":"Rico-Hesse","year":"2003","journal-title":"Adv Virus Res"},{"key":"key\n\t\t\t\t20171014000805_ref10","first-page":"311","article-title":"Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered","volume":"42","author":"Halstead","year":"1970","journal-title":"Yale J Biol Med"},{"key":"key\n\t\t\t\t20171014000805_ref11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4269\/ajtmh.1990.42.179","article-title":"Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study","volume":"42","author":"Guzman","year":"1990","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20171014000805_ref12","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.4049\/jimmunol.176.5.2825","article-title":"The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection","volume":"176","author":"Huang","year":"2006","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20171014000805_ref13","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.3277268","article-title":"Pathogenesis of dengue: challenges to molecular biology","volume":"239","author":"Halstead","year":"1988","journal-title":"Science"},{"key":"key\n\t\t\t\t20171014000805_ref14","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1086\/500949","article-title":"Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement","volume":"193","author":"Avirutnan","year":"2006","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171014000805_ref15","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1016\/j.vaccine.2004.11.069","article-title":"Recombination and flavivirus vaccines: a commentary","volume":"23","author":"Monath","year":"2005","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014000805_ref16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690005","article-title":"Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii","volume":"69","author":"Halstead","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20171014000805_ref17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0264-410X(00)00040-2","article-title":"Live attenuated tetravalent dengue vaccine","volume":"18","author":"Bhamarapravati","year":"2000","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014000805_ref18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690024","article-title":"Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates","volume":"69","author":"Sun","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20171014000805_ref19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4269\/ajtmh.2003.69.48","article-title":"Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine","volume":"69","author":"Edelman","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20171014000805_ref20","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1016\/S0264-410X(01)00020-2","article-title":"Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers","volume":"19","author":"Kanesa-Thasan","year":"2001","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014000805_ref21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.inf.0000109289.55856.27","article-title":"Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children","volume":"23","author":"Sabchareon","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20171014000805_ref22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4269\/ajtmh.2002.66.264","article-title":"Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses","volume":"66","author":"Sabchareon","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20171014000805_ref23","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1016\/j.vaccine.2006.03.066","article-title":"Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)","volume":"24","author":"Sanchez","year":"2006","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014000805_ref24","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.vaccine.2005.09.029","article-title":"Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults","volume":"24","author":"Kitchener","year":"2006","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014000805_ref25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.2001.65.405","article-title":"Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3\u2032-untranslated region","volume":"65","author":"Durbin","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20171014000805_ref26","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/427780","article-title":"rDEN4\u03b430, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers","volume":"191","author":"Durbin","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171014000805_ref27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4269\/ajtmh.2001.65.414","article-title":"A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes","volume":"65","author":"Troyer","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20171014000805_ref28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0065-3527(03)61013-4","article-title":"Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis","volume":"61","author":"Lai","year":"2003","journal-title":"Adv Virus Res"},{"key":"key\n\t\t\t\t20171014000805_ref29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity","volume":"2","author":"Guirakoo","year":"2006","journal-title":"Hum Vaccin"},{"key":"key\n\t\t\t\t20171014000805_ref30","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.vaccine.2005.03.042","article-title":"An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model","volume":"23","author":"Putnak","year":"2005","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014000805_ref31","volume-title":"Guidelines for the evaluation of dengue vaccines in populations exposed to natural infection","author":"World Health Organization (WHO)","year":"2002"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/45\/Supplement_1\/S56\/20907671\/45-Supplement_1-S56.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T00:08:14Z","timestamp":1507939694000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/45\/Supplement_1\/S56\/357828\/Dengue-Vaccines-Approach-the-Finish-Line"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,15]]},"references-count":31,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2007,7,15]]},"published-print":{"date-parts":[[2007,7,15]]}},"URL":"https:\/\/doi.org\/10.1086\/518148","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1088863.541860","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1088863.542889","asserted-by":"object"}]},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2007,7,15]]},"published":{"date-parts":[[2007,7,15]]}}}